Back to competency map

Clinical competency

Physical safety monitoring

Cluster covering 3 related competencies including: Physical safety monitoring, Safety monitoring during dosing sessions, Medical safety monitoring during psilocybin administration.

Primary clinical guidelineModern clinical

Looking for something specific? Ask Blossom

Guidelines

19

Courses

0

Providers

0

Protocols

5

Classification

Source quality

Lab manualProtocol paperSOP / guidebookTrial supplement

Also known as

Continuous observation during dosingContinuous safety observation during dosing sessionsDose administration and session monitoringMedical and physiologic monitoring during dosing sessionsMedical safety awareness during dosingMedical safety monitoring during Experimental SessionsMedical safety monitoring during psilocybin administrationMedical safety readiness and physiological monitoringMonitor physical safety during sessionsPhysical and cardiovascular safety monitoringSafety monitoring during ayahuasca sessionsSafety monitoring during dosing sessionSafety monitoring during dosing sessionsSafety monitoring for adverse physical reactionsSupervised observation and supportVital sign monitoring and physiological safety surveillance

Across the manuals

The manuals converge on close, continuous monitoring of participants during dosing sessions, with repeated attention to vital signs, physical stability, and signs of acute distress. Across MDMA, psilocybin, ayahuasca, and ibogaine protocols, the sources repeatedly describe observation for nausea, vomiting, dizziness, agitation, panic, confusion, psychosis, or other adverse reactions, alongside practical support such as helping with movement, hydration, and safe discharge. They also converge on the idea that safety takes priority over the session itself. Several manuals explicitly mention escalation to a physician, medical monitor, or emergency support when symptoms worsen, and some add readiness measures such as emergency support availability, discharge criteria, or withholding supplemental dosing when safety concerns arise. Sources differ mainly in the specific monitoring emphasis. MDMA manuals place stronger weight on cardiovascular and thermoregulatory monitoring, hydration limits, and fall prevention, while psilocybin manuals more often stress constant observation, emotional and physical support, and remaining with the participant until acute effects subside. Ayahuasca protocols give more attention to nausea, vomiting, blood pressure, and post-acute vigilance, and ibogaine materials emphasise prolonged observation and repeated checks over a longer post-dose period.

In practice

What it looks like on the ground

  • Checks blood pressure, pulse, temperature, or other vital signs during the session
  • Stays in the room or nearby for continuous observation and support
  • Assists with walking, standing, bathroom use, or other mobility needs to reduce fall risk
  • Escalates concerns to a physician, medical monitor, or emergency support when symptoms worsen

Synthesised from the linked source documents; refreshed as the library updates.

Linked sources

The guidelines, courses, and providers that evidence this competency. Full lists are a Blossom Pro feature.

Linked guidelines (19)

  • A Phase 1/2 Study of a Group Model of Psilocybin-Assisted Therapy for Cancer-Related Anxiety in Patients With Metastatic Cancer

    PsilocybinEvidence score: 90

Unlock every linked source

See all linked guidelines, courses, and providers behind this competency, plus the full competency graph.